For CRO Partners
DF Clinical brings US clinical development leadership to solid tumor oncology programs executed in Asia Pacific markets where site and operational costs are often a fraction of US cost. We have a particular focus on early phase clinical trials.
For CRO partners who need therapeutically relevant medical leadership on Asia Pacific CRO services work, we plug in at the strategy and execution layers: protocol judgment, medical monitoring, enrollment support, and CRO oversight, without asking you to rebuild a senior US clinical team for every APAC study.
The Opportunity
Asian clinical trials and broader Asia Pacific clinical trials capacity have matured for oncology sponsors who need speed, enrollment, and cost discipline without sacrificing medical quality. The constraint is usually not interest in the region. It is whether the program has physician leadership that understands both US regulatory expectations and how the study actually runs on the ground.
DF Clinical is built for that gap. We are not positioning as another full service CRO. We provide clinical development leadership and oncology clinical trial services that CROs and sponsors use when a solid tumor program needs senior medical depth across APAC execution.
What stays constant
Cost
Clinical trial outsourcing to APAC is often driven by overseas clinical trials cost. For many solid tumor programs, site fees, investigator costs, and day to day operations in Thailand, Malaysia, and Australia can run at a fraction of comparable US cost, while still supporting rigorous oncology protocols.
Cost effective clinical trials are not the same as under resourced trials. The way we keep quality intact is simple: US physician leadership owns the clinical judgment; regional execution carries the operational load.
We do not publish fabricated percentage savings. In a consultation we can walk through where APAC typically reduces burn for your indication, phase, and site mix, and where US or other regions still belong in the plan.
The Region
Thailand is a practical setting for oncology clinical trials when sponsors need experienced investigators, competitive cost structure, and patients with solid tumor disease burden relevant to global programs. DF Clinical's APAC work includes Southeast Asia relationships built through multi region trial conduct and regional CRO collaboration.
Malaysia complements Thailand for Asian clinical trials that need additional sites, regulatory pathways suited to early and mid phase oncology, and cost effective clinical trial operations under US medical oversight.
Clinical trials in Australia are a frequent APAC anchor for early phase oncology clinical trials: strong investigator networks, English language operations, and regulatory familiarity for sponsors who already run US and EU work. We treat Australia as part of a multi country APAC execution story, not a standalone patient registry page.
Together, Thailand, Malaysia, and Australia give CRO partners a cost and enrollment map that is hard to recreate with US sites alone, while DF Clinical keeps medical leadership aligned to US expectations.
Scope
This page is not a general therapeutic menu. The pathway is limited to solid tumor clinical trials and related oncology clinical trial services.
Areas of concentrated experience on the oncology side include solid tumors such as metastatic colorectal cancer, hepatocellular carcinoma, and non-small cell lung cancer, across modalities that include cancer immunotherapy, allogeneic cell therapy, oncolytic viruses, and targeted small molecules. Early phase oncology clinical trials are a natural fit when sponsors need tight medical monitoring, eligibility discipline, and enrollment troubleshooting. Where this depth sits in the wider network is described under therapeutic area expertise.
If the program is outside oncology or solid tumors, we will say so plainly and point you elsewhere.
Engagement Model
CROs specializing in oncology clinical trials often need supplemental physician depth for a given study or region. DF Clinical is set up for that engagement model.
You keep delivery ownership. We supply the medical leadership that makes Asia Pacific CRO services feel as governed as a US led program.
Common Questions
Outsourcing support and medical leadership. We are not replacing your CRO. We strengthen oncology programs that are already being outsourced or co-delivered across APAC.
Usually in site and operational line items relative to US sites. Exact savings depend on phase, indication, and country mix. We discuss that in a short consult rather than promising a fixed percentage on a webpage.
Early phase oncology clinical trials are a strong fit. Later phase solid tumor work is also in scope when the medical leadership need is clear.
Therapeutic depth lives on Therapeutic Expertise. Ongoing physician review lives on Medical Monitoring. Feasibility and enrollment live on Site Feasibility & Enrollment. This page owns the APAC cost and multi country oncology execution story for CRO partners.
Describe the indication, phase, and where Thailand, Malaysia, and/or Australia sit in the plan. We will tell you plainly whether this is the right kind of help.
david@dfclinical.com